In this paper, we identified a cocrystal conglomerate of mandelic acid using a drug compound as a coformer. We then developed a chiral resolution process based on preferential cocrystallization. Several versions of such a process were explored and optimized, leading to a successful resolution of mandelic acid, evidencing the efficiency of our system. Excellent enantiopurity (98–99%) was obtained with a process that can run for multiple cycles.

In this work, we are the first to identify thirteen cocrystals of Nefiracetam, a poor water-soluble nootropic compound. Three of which were obtained with the biocompatible cocrystallization agents citric acid, oxalic acid, and zinc chloride. These latter have been fully structurally and physically characterized and the solubility, dissolution rate, and stability were compared to that of the initial Active Pharmaceutical Ingredient (API).

The structure of K5(HPO4)2(H2PO4)·H2O was determined via single crystal diffraction. The crystal structures of phosphate salts of potassium have been known since the early days of crystallography. Here, we present a new monohydrate adduct between K2HPO4 and KH2PO4.

Pyruvic acid is an organic compound used in various fields (e.g., the pharmaceutical, cosmetic, food, and chemical industries) and subject to constantly growing demand. Pyruvic acid is liquid at room temperature, rendering manipulation less straightforward. Furthermore, in the liquid phase, pyruvic acid is air-sensitive. We here present a multi-component crystal engineering strategy to render pyruvic acid solid under ambient conditions, focusing on cocrystallization and salt formation. Out of 73 screened cocrystal and salt formers, eight were found to form novel crystalline forms with pyruvic acid. Four of these were studied in detail, with pyruvic acid stable in a solid phase at temperatures up to 120 °C. These results illustrate the effectiveness of cocrystallization as a tool to convert unstable liquid compounds into stable crystalline solid forms.